Patents Examined by Bao Q Li
  • Patent number: 10946088
    Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 16, 2021
    Assignee: Seqirus UK Limited
    Inventors: Christoph Haussmann, Frank Hauschild, Bjorn Jobst
  • Patent number: 10947513
    Abstract: The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 16, 2021
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Patent number: 10942181
    Abstract: The present disclosure provides a method for quantifying a vaccine. The method includes the steps of: 1) providing a plurality of standard mixtures, each of the standard mixtures having a standard antigen and an aluminum based adjuvant; 2) mixing a stabilizing solution with the vaccine and each of the standard mixtures; 3) determining dosages of the standard antigens in the standard mixtures to establish a standard curve; and 4) determining a dosage of a target antigen in the vaccine according to the standard curve.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 9, 2021
    Assignee: Adimmune Corporation
    Inventors: Juine-Ruey Chen, Chia-Ying Wu, Yung-Tsung Chen
  • Patent number: 10940196
    Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 9, 2021
    Assignee: BIOGENESIS BAGÓ HONG-KONG LIMITED
    Inventors: Rodolfo César Bellinzoni, Emmanuel Gérard Etienne Régulier, Ana Romo
  • Patent number: 10940202
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 9, 2021
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Patent number: 10925956
    Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 23, 2021
    Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/S
    Inventors: Benoit Christophe Stephan Callendret, Ramon Roozendaal, Jutta Sytske Hartkoorn-Pasma, Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier
  • Patent number: 10925961
    Abstract: Disclosed herein is a vaccine comprising an antigen and CD40L. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 23, 2021
    Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS. INC.
    Inventors: David Weiner, Matthew Morrow, Megan Wise
  • Patent number: 10913776
    Abstract: Disclosed is an immunogen comprising a fusion protein, wherein the fusion protein comprises a Zika virus (ZIKV) envelope protein, optionally a signal peptide, and a multimerization domain. The signal peptide is a premembrane (prM) signal peptide, an IgG signal peptide, or a human secretory signal peptide hidden Markov model, and the multimerization domain is an immunoglobulin Fc domain, a T4 fibritin foldon trimerization domain, or a human collagen XV trimerization domain. Nucleic acids, vectors, and microneedle arrays including these compositions are disclosed. Methods of producing an immune response to ZIKV are also disclosed.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Andrea A. Gambotto, Eun Kim, Geza Erdos, Louis D. Falo, Jr.
  • Patent number: 10905760
    Abstract: Disclosed herein are chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS 1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: February 2, 2021
    Assignee: Svenska Vaccinfabriken Produktion AB
    Inventors: Matti Sällberg, Lars Frelin
  • Patent number: 10900025
    Abstract: The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 26, 2021
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Connor McBrine, Georgiana Kourepenos, Parker Dow, Jason Holder
  • Patent number: 10894831
    Abstract: Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 19, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter Schnorr, Akanksha Chhabra, Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf
  • Patent number: 10889649
    Abstract: Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 12, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roy Louis Maute, Kipp Andrew Weiskopf, Aaron Michael Ring, Irving L. Weissman
  • Patent number: 10889633
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 12, 2021
    Assignees: The Rockefeller University, California Institute of Technoloqy
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Patent number: 10881722
    Abstract: The present disclosure provides for an immunogenic composition against epizootic hemorrhagic disease virus (EHDV). The immunogenic composition has been shown to be efficacious in inducing serum neutralizing antibodies against EHDV and intended to be used to prevent or reduce clinical symptoms associated with EHDV infection in susceptible animals. The disclosure provides for composition and methods that represent an improvement over previous strategies for treating and preventing EHDV.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 5, 2021
    Assignees: Kansas State University Research Foundation, The United States of America, as reoresented by The Secretary of Agriculture
    Inventors: Juergen A. Richt, Igor Morozov, Sun Young Sunwoo, William C. Wilson
  • Patent number: 10882886
    Abstract: Polypeptides are encoded by an adeno-associated virus (AAV)-derived endogenous viral element (mAAV-EVE1) found within the germline of numerous closely-related marsupial species. Nucleic acid molecules encode the polypeptides. Vectors can include the nucleic acid molecules, and recombinant AAV virions can include the polypeptides. A chimeric capsid protein can also include an MAAV-EVE1 polypeptide.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 5, 2021
    Assignees: CHILDREN'S MEDICAL RESEARCH INSTITUTE, THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD) (INCORPORATING THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN), THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (WASHINGTON DC)
    Inventors: Claus Hallwirth, Ian Alexander, Richard Smith, Robert Kotin
  • Patent number: 10883991
    Abstract: The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by SEQ ID NO: 1; the CDR2 includes an amino acid sequence represented by SEQ ID NO: 2; and the CDR3 includes an amino acid sequence represented by SEQ ID NO: 3. The antibody is capable of binding to an intranuclear protein of an influenza virus.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 5, 2021
    Assignee: PANASONIC INTELLECTURAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Emina Ikeuchi
  • Patent number: 10881725
    Abstract: The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: January 5, 2021
    Assignee: Bavarian Nordic A/S
    Inventors: Robin Steigerwald, Markus Kalla
  • Patent number: 10876097
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: December 29, 2020
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • Patent number: 10865228
    Abstract: Described herein is the generation of optimized H5N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: December 15, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Brendan M. Giles
  • Patent number: 10857225
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: December 8, 2020
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev